Last reviewed · How we verify

NCT05672654

Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients

Withdrawn NA Last updated 19 September 2024
What this trial tests

NA trial testing Blood draw in HIV Seropositivity. Withdrawn.

Timeline
10 May 2021
Primary endpoint
1 September 2023
1 September 2023

Quick facts

Lead sponsorUniversity Hospital, Ghent
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposescreening
Start date10 May 2021
Primary completion1 September 2023
Estimated completion1 September 2023
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Ghent

Who can join

Adults 16 to 100, any sex, with HIV Seropositivity or Immunodeficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to identify both the humoral immunological response through the detection of induced antibodies and the cellular immunological response through the detection of interferon gamma production by functional CD4+ and CD8+ cells in different groups of immunocompromised patients. For antibody detection, LIAISON® SARS-CoV-2 TrimericS assay (DiaSorin) will be used and for the evaluation of cellular immunity - QuantiFERON SARS-CoV-2 assay (QIAGEN).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood draw

Trials testing the same drug.

Other recruiting trials for HIV Seropositivity

Currently open trials in the same condition.

Other University Hospital, Ghent trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672654.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing